N4 PHARMA PLC — Director's Dealing 2016

Aug 3, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1048G

Verona Pharma PLC

03 August 2016

i

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii		Verona Pharma plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights			√
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: iii	Vivo Ventures VI, LLC
4. Full name of shareholder(s) (if different from 3.):iv	Vivo Ventures fund VI, LP Vivo Ventures VI Affiliates Fund, LP
5. Date of the transaction and date on which the threshold is crossed or reached: v	July 29, 2016
6. Date on which issuer notified:	July 29, 2016
7. Threshold(s) that is/are crossed or reached: vi, vii	1.62% to 2.46% Change at Combined Interest Level

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction		Resulting situation after the triggering transaction
Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of  voting rights x
Direct	Direct xi	Indirect xii	Direct	Indirect
GB00B06GSH43	16,400,000	16,400,000	63,098,468		63,098,468		2.46%

B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument	Expiration date xiii	Exercise/ Conversion Period xiv	Number of voting rights that may be acquired if the instrument is exercised/ converted.	% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument	Exercise price	Expiration date xvii	Exercise/ Conversion period xviii	Number of voting rights instrument refers to	% of voting rights xix, xx
					Nominal	Delta

Total (A+B+C)
Number of voting rights	Percentage of voting rights
63,098,468	2.46%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Vivo Ventures VI, LLC is the general partner of both Vivo Ventures Fund VI, LP (VV Fund VI) and Vivo Ventures VI Affiliates Fund, LP. (Affiliates Fund VI). Accordingly, Vivo Ventures VI,  LLC may be deemed to have indirect beneficial ownership of shares of the Issuer directly owned by VV Fund VI and Affiliates Fund VI. As of the date of this filing, VV Fund VI and Affiliates

Fund VI beneficially own 62,639,570 and 458,898 shares of Common respectively.

Proxy Voting:
10. Name of the proxy holder:	See Section 4
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:
14. Contact name:	Vivo Capital, LLC Attn: Cinthia Sheu
15. Contact telephone number:	+1-650-688-0818

Note: Annex should only be submitted to the FCA not the issuer

Annex: Notification of major interests in sharesxxii

A: Identity of the persons or legal entity subject to the notification obligation
Full name (including legal form of legal entities)	Vivo Ventures VI, LLC
Contact address (registered office for legal entities)	575 High Street, suite 201, Palo Alto, CA 94301
Phone number & email	650-688-0818; acha@vivocapital.net
Other useful information (at least legal representative for legal persons)	Albert Cha, Managing Member

B: Identity of the notifier, if applicable
Full name	Albert Cha
Contact address	575 High Street, suite 201, Palo Alto, CA 94301
Phone number & email	650-688-0818; acha@vivocapital.net
Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation)	Albert Cha, Managing Member

C: Additional information

For notes on how to complete form TR-1 please see the FCA website.

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLUGUUWRUPQUMW